Factive Indications/Uses

Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed as follows.
Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumonia, or Klebsiella pneumonia.
*MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin resistant Streptococcus pneumonia), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2^nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Factive and other antibacterial drugs, Factive should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.